This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Vifor Pharma マネジメント

マネジメント基準チェック /24

主要情報

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	6.8yrs
取締役会の平均在任期間	3.4yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Vifor Pharma CEOがいない、あるいは彼らに関するデータがない。

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Alexandros Sigalas	Acting CFO & Head of IT & Administration	6.8yrs	データなし	データなし
Frederic Zwahlen	Head of Technical Operations	less than a year	データなし	データなし
Julien Vignot	Head of Investor Relations & Treasury	5.8yrs	データなし	データなし
Oliver Kronenberg	Group General Counsel	8.8yrs	データなし	データなし
Nathalie Ponnier	Global Head Corporate Communications	no data	データなし	データなし
Michael Puri	Chief Human Resources Officer	7.4yrs	データなし	0.014% $ 1.7m
Christoph Springer	Chief Strategy Officer	6.8yrs	データなし	0.052% $ 6.1m
Thomas Kaspar	Head of Global Quality Management	11.8yrs	データなし	データなし
Thierry Teil	Head of Global Medical Affairs	6.8yrs	データなし	データなし
Carolina Ponchione	Head of Executive Search & Employer Branding	4.8yrs	データなし	データなし
Barbara Angehrn	Chief Business Officer	3.9yrs	データなし	0.0027% $ 315.0k
Antonio Jordao	Regional Head of Southern Europe	no data	データなし	データなし

6.8yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: GNHA.F's management team is seasoned and experienced (6.8 years average tenure).

取締役

名称	ポジション	在職期間	報酬	所有権
Jacques Theurillat	Independent Chairman of the Board	4.4yrs	CHF 1.20m	0.0066% $ 776.4k
Asa Riisberg	Independent Director	1.4yrs	CHF 133.00k	データなし
Etienne Jornod	Honorary Chairman	2.4yrs	CHF 3.33m	データなし
Alexandre Lebeaut	Independent Director	1.4yrs	CHF 117.00k	データなし
Michel Burnier	Independent Director	12.8yrs	CHF 231.00k	0.017% $ 2.0m
Romeo Cerutti	Independent Vice Chairman & Lead Independent Director	7.8yrs	CHF 326.00k	0.015% $ 1.7m
Kim Stratton	Independent Director	3.4yrs	CHF 211.00k	0.0019% $ 217.8k
Susan Mahony	Independent Director	3.4yrs	CHF 260.00k	0.0022% $ 256.5k

3.4yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: GNHA.F's board of directors are considered experienced (3.4 years average tenure).

This company has been acquired

Vifor Pharma マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Announces Board Changes

Recent updates

Vifor Pharma AG Common Shares to Be Deleted from OTC Equity

SIX Exchange Regulation Approves Delisting of Vifor Pharma AG's Registered Shares

CSL Behring AG completed the acquisition of a 93.99% stake in Vifor Pharma AG (SWX : VIFN) from a group of shareholders.

Vifor Pharma AG(SWX:VIFNE) dropped from FTSE All-World Index (USD)

Vifor Pharma Announces Resignation of Abbas Hussain as CEO

Vifor Pharma Ag Approves Dividend, Will Be Paid to Shareholders from 3 May 2022

Vifor Pharma Ag Announces Full Results from Its Phase-IIIb Diamond Trial

Vifor Pharma AG(SWX:VIFN) dropped from Swiss Performance Index (Price Return)

CSL Plans to Pursue an Application to SIX Exchange Regulation for the Delisting of the Vifor Pharma Shares

Vifor Pharma Group Appoints Two New Members to the Executive Committee

Vifor Pharma Reports Positive Outcome of the Phase-IIIb Diamond Trial of Veltassa®

Vifor Pharma and American Regent Announce Settlement Agreements with Mylan Laboratories Ltd., and Sandoz, Inc., of Injectafer Patent Litigation

Corden Pharma International Gmbh agreed to acquire Finished Drug Product Manufacturing Business of Vifor Pharma Group.

Vifor Pharma and CSL Confirm Merger Talks

Vifor Pharma AG Announces Enrolmenet of First Patient in Phase-IIa Study of Vamifeport in Patients with Sickle Cell Disease

Angion Biomedica Corp. and Vifor Pharma AG Report Topline Results from Phase 2 Guard Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

Vifor Says Regularly in Talks with Other Market Participants After Reports

Vifor Pharma AG (SWX:VIFN) entered into a definitive agreement to acquire Sanifit Therapeutics S.A. from group of investor for €375 million.

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Vifor Pharma Group Provides Earnings Guidance for the Year 2021

Vifor Pharma to Revise DIAMOND Study

Vifor Pharma AG Approves Dividend, Payable from 12 May 2021

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Vifor Pharma AG Provides Phase-II Clinical Trial of VIT-2763 in Non-Transfusion-Dependent Beta-Thalassemia Is Expected to Be Completed in the Second Half of 2021

Vifor Pharma Announces Board Changes

Vifor Pharma Presents the Full Results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Optimus Holding Ltd. completed the acquisition of OM Pharma SA from Vifor Pharma AG (SWX:VIFN).

Vifor Pharma Announces Outcome of AFFIRM-AHF Topline Data

Vifor Pharma AG to Report First Half, 2021 Results on Jul 28, 2021

CEO（最高経営責任者

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24